EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Actinogen Medical Limited (ATGGF) fair value: what the stock is really worth

As of Sep 25, 2026: fair value of Actinogen Medical Limited $0.02, price $0.06, upside -61.7%, quality 28 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · US · ISIN AU000000ACW3

AM Actinogen Medical Limited logo Thin data Sep 13, 2026

Actinogen Medical Limited

ATGGF · US

Weakest SetupStrongly overvalued and low quality.

!Fair value $0.0230 · Strongly overvalued (−61.7%)
!Quality 28/100
!Mixed Growth (revenue 5y +9.3 %/yr)
!Low debt · negative free cash flow
!Narrow moat 5/100
!Evidence only low, so the estimate is less certain

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$0.0947 $0.0008 Fair Value $0.0230 Sep 2018 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 13, 2026.

How to read this chart

60‑month range $0.0008 – $0.0947 · the $0.0600 price screens above the $0.0230 fair value. Dashed = 300-day average. As of Sep 13, 2026.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia.

Show more

Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia. It develops Xanamem, an oral medication and inhibitor of the 11ß-HSD1 enzyme that achieves target engagement in the brain for the treatment of Alzheimer's disease, major depressive disorder, fragile x syndrome, and other neurological diseases. The company was formerly known as Actinogen Limited and changed its name to Actinogen Medical Limited in November 2015. Actinogen Medical Limited was incorporated in 1999 and is based in Sydney, Australia.

Stock analysis

Actinogen Medical Limited (ATGGF) currently trades at $0.0600, while our model-based Fair Value estimate is $0.0230, 61.7% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.

Quality & growth

The Quality Score stands at 28/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Actinogen Medical Limited reported revenue of A$5.5M in FY2025 versus A$2.0M in FY2021, a compound +29.0%/yr. Reported net income was −A$14.7M in FY2025.

Key figures

Market cap $2.9M · P/S ratio 0.39 · Net margin −243% · Return on equity −111% · Return on assets (EBIT) −49.8% · Operating margin −609% · Revenue (TTM) A$7.4M · Revenue growth (YoY) −39.2%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 27 out of 100 (low confidence).

What moves the price

The share trades about 50% above its previous 52-week high, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −62%, ATGGF screens richer than that median.

Notify me when ATGGF reaches fair value

Put ATGGF on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 28/100

Of which business quality 31 · Market factors (momentum, volatility) 67

Profitability 10
Margins and returns on capital today
Quality Growth 22
Are margins and returns improving?
Cashflow 0
Earnings quality: real cash, not paper profit
Fin. Strength 73
Balance sheet, leverage, solvency risk
Investment 97
Disciplined investing over empire-building
Low Volatility 38
Calm price path (market factor)
Momentum 67
Price trend over the last 3–12 months (market factor)
52W Momentum 100
Distance to the 52-week high (market factor)
Net Issuance 0
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 19/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−44.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.3%
Start year 2020 (pandemic). Over 10 years: +43.0% a year
Revenue growth 17 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+23.3%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−253.4% (2020) → −272.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

ATGGF screens overvalued: fair value 62% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Actinogen Medical Limited with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $527.67 $580.44 +10%
Regeneron Pharmaceuticals, Inc REGN $752.25 $1,275 +69%
argenx SE ARGX $959.49 $918.60 −4%
CSL Limited CSL A$175.35 A$192.89 +10%
Samsung Biologics Co 207940 1,354,000 KRW 1,489,400 KRW +10%
BeOne Medicines AG ONC $360.85 $280.94 −22%
Alnylam Pharmaceuticals, Inc ALNY $255.96 $217.88 −15%
Royalty Pharma plc RPRX $58.21 $19.01 −67%
Celltrion, Inc 068270 177,400 KRW 74,519 KRW −58%
WuXi Biologics (Cayman) Inc 2269 HK$53.00 HK$58.30 +10%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Actinogen Medical Limited · Fair Value
$0.0230 −62%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Actinogen Medical Limited Fair Value". https://www.fairvalue-calculator.com/stock/ATGGF

Frequently asked questions

Is Actinogen Medical Limited (ATGGF) overvalued or undervalued?
As of Sep 13, 2026, our model estimates a fair value of $0.0230 versus the last price from Sep 25, 2026 of $0.0600, about −62% upside (overvalued).
What is the fair value of ATGGF?
Our model-based fair value for Actinogen Medical Limited is $0.0230 (as of Sep 13, 2026), built from audited fundamentals. Last price (from Sep 25, 2026): $0.0600.
What is the quality score of ATGGF?
Actinogen Medical Limited has a Quality Score of 28/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Actinogen Medical Limited (ATGGF)?
Our model-based price target is the fair value of $0.0230 (as of Sep 13, 2026) from 1 valuation models. It is a calculation from audited fundamentals, not an analyst target.
What is the Actinogen Medical Limited stock forecast for 2026?
Our models put fair value at $0.0230, about −62% upside versus the last price from Sep 25, 2026 of $0.0600 (overvalued). The calculation is refreshed regularly with new filings.
What is the revenue of Actinogen Medical Limited (ATGGF)?
Actinogen Medical Limited reported trailing-twelve-month revenue of about A$7.4M (latest available figure, as of Sep 13, 2026).
What is the intrinsic value of Actinogen Medical Limited (ATGGF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Actinogen Medical Limited it is $0.0230 per share (as of Sep 13, 2026), against a price of $0.0600. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Actinogen Medical Limited stock overvalued or undervalued in 2026?
As of Sep 13, 2026, ATGGF trades above its calculated fair value: price $0.0600, fair value $0.0230, a gap of about −62% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ATGGF?
No. The price is what the market pays today ($0.0600); the fair value is what the company's own numbers justify ($0.0230). For Actinogen Medical Limited the two are $0.0370 per share apart. That gap is exactly why we show both numbers side by side.
How much is Actinogen Medical Limited worth?
The market values Actinogen Medical Limited at about $2.9M (market capitalisation, as of Sep 13, 2026). Per share that is $0.0600; our models calculate a fair value of $0.0230 per share.
How far is ATGGF from its 52-week high?
Actinogen Medical Limited trades at $0.0600, about 50% above its previous 52-week high of $0.0400 and 7,400% above the low of $0.0008 (as of Sep 25, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0230 is for.
Which stocks are comparable to Actinogen Medical Limited?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Actinogen Medical Limited stock attractive at the current price?
The data as of Sep 13, 2026: price $0.0600, calculated fair value $0.0230 (−62%), Quality Score 28/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ATGGF calculated?
We run Actinogen Medical Limited through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.0230, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Actinogen Medical Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Actinogen Medical Limited (ATGGF)?
The latest price we hold is from Sep 25, 2026 and stands at $0.0600. Our model-based fair value is $0.0230, about −62% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Actinogen Medical Limited right now?
Weak quality (28/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Actinogen Medical Limited

How large is the market capitalisation of Actinogen Medical Limited (ATGGF)?
The market capitalisation of Actinogen Medical Limited is $2.9M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Actinogen Medical Limited (ATGGF)?
The price-to-sales ratio of Actinogen Medical Limited is 0.39 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Actinogen Medical Limited (ATGGF)?
The net margin of Actinogen Medical Limited is −243% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Actinogen Medical Limited (ATGGF)?
The return on equity (ROE) of Actinogen Medical Limited is −111% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Actinogen Medical Limited (ATGGF)?
On an EBIT basis the return on assets of Actinogen Medical Limited is −49.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Actinogen Medical Limited (ATGGF)?
The operating margin of Actinogen Medical Limited is −609% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Actinogen Medical Limited (ATGGF)?
Revenue at Actinogen Medical Limited is growing −39.2% versus a year earlier (3y avg +14.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Actinogen Medical Limited (ATGGF) generate?
The free cash flow of Actinogen Medical Limited is −A$7.6M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Actinogen Medical Limited (ATGGF) hold?
Actinogen Medical Limited holds more cash than debt, A$13.2M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Continue in the live analysis

Fair value and trend for 35,000+ stocks, watchlist, comparison and the diversification check. You can also try 14 days of Pro there, no card.

Open the live analysis →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.